Di Caro Simona, Zocco Maria Assunta, Cremonini Filippo, Candelli Marcello, Nista Enrico C, Bartolozzi Francesco, Armuzzi Alessandro, Cammarota Giovanni, Santarelli Luca, Gasbarrini Antonio
Pathology Department, UPMC, Pittsburgh, PA, USA.
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1309-12. doi: 10.1097/00042737-200212000-00004.
A 7 day treatment scheme based on rabeprazole/levofloxacin/amoxycillin or tinidazole achieved an eradication rate over 90%. However, the combination of drugs and duration of treatment for the correct use of levofloxacin in the eradication of are still unclear.
To compare the efficacy and tolerability of rabeprazole/levofloxacin based dual therapies given for 5, 7 or 10 days with rabeprazole/levofloxacin/amoxycillin triple therapy for 7 days.
One hundred and sixty patients with infection documented by the C-urea breath test and histology were included in this prospective, open label study. Subjects were randomized in four groups: (1) levofloxacin (500 mg o.d.), amoxycillin (1 g b.d.) and rabeprazole (20 mg o.d.) for 7 days; (2) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 5 days; (3) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 7 days; and (4) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 10 days. Six weeks after the end of therapy status was checked by using the C-urea breath test.
All patients completed the therapeutic regimens. The eradication rate was not significantly modified by treatment duration in the dual therapy schemes (5 days: 20/40, 50%; 7 days: 28/40, 70%; 10 days: 26/40, 65%). The eradication rate of the 1 week levofloxacin based triple therapy was significantly higher than that observed using any dual therapies (36/40). No major adverse effects were observed.
A rabeprazole/levofloxacin dual eradication regimen is simple and well tolerated but does not achieve an acceptable eradication rate when compared to a 1 week rabeprazole/levofloxacin/amoxycillin triple therapy. The eradication rate did not increase with a longer regimen.
基于雷贝拉唑/左氧氟沙星/阿莫西林或替硝唑的7天治疗方案根除率超过90%。然而，在根除治疗中左氧氟沙星正确使用的药物组合及疗程仍不明确。
比较雷贝拉唑/左氧氟沙星双药疗法分别治疗5天、7天或10天与雷贝拉唑/左氧氟沙星/阿莫西林三联疗法治疗7天的疗效和耐受性。
本前瞻性、开放标签研究纳入160例经C尿素呼气试验和组织学证实感染的患者。受试者被随机分为四组：（1）左氧氟沙星（500毫克，每日一次）、阿莫西林（1克，每日两次）和雷贝拉唑（20毫克，每日一次），疗程7天；（2）左氧氟沙星（500毫克，每日一次）和雷贝拉唑（20毫克，每日一次），疗程5天；（3）左氧氟沙星（500毫克，每日一次）和雷贝拉唑（20毫克，每日一次），疗程7天；（4）左氧氟沙星（500毫克，每日一次）和雷贝拉唑（20毫克，每日一次），疗程10天。治疗结束6周后，采用C尿素呼气试验检查治疗状态。
所有患者均完成治疗方案。双药疗法中，疗程对根除率无显著影响（5天：20/40，50%；7天：28/40，70%；10天：26/40，65%）。基于左氧氟沙星的1周三联疗法的根除率显著高于任何双药疗法（36/40）。未观察到严重不良反应。
雷贝拉唑/左氧氟沙星双药根除方案简单且耐受性良好，但与1周的雷贝拉唑/左氧氟沙星/阿莫西林三联疗法相比，未达到可接受的根除率。疗程延长，根除率并未增加。
